Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10916224 | Nuclear Medicine and Biology | 2005 | 8 Pages |
Abstract
This study describes the preliminary positron emission tomography (PET) evaluation of a dopamine D2-like receptor agonist, (R)-2-11CH3O-N-n-propylnorapomorphine ([11C]MNPA), as a potential new radioligand for in vivo imaging of the high-affinity state of the dopamine D2 receptor (D2R). MNPA is a selective D2-like receptor agonist with a high affinity (Ki=0.17 nM). [11C]MNPA was successfully synthesized by direct O-methylation of (R)-2-hydroxy-NPA using [11C]methyl iodide and was evaluated in cynomolgus monkeys. This study included baseline PET experiments and a pretreatment study using unlabeled raclopride (1 mg/kg). High uptake of radioactivity was seen in regions known to contain high D2R, with a maximum striatum-to-cerebellum ratio of 2.23±0.21 at 78 min and a maximum thalamus-to-cerebellum ratio of 1.37±0.06 at 72 min. The pretreatment study demonstrated high specific binding to D2R by reducing the striatum-to-cerebellum ratio to 1.26 at 78 min. This preliminary study indicates that the dopamine agonist [11C]MNPA has potential as an agonist radioligand for the D2-like receptor and has potential for examination of the high-affinity state of the D2R in human subjects and patients with neuropsychiatric disorders.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Sjoerd J. Finnema, Nicholas Seneca, Lars Farde, Evgeny Shchukin, Judit Sóvágó, Balázs Gulyás, HÃ¥kan V. Wikström, Robert B. Innis, John L. Neumeyer, Christer Halldin,